UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): February 12, 2021

Date of Report (Date of earliest event reported): February 11, 2021

Urovant Sciences Ltd.

(Exact name of Registrant as Specified in Its Charter)

Bermuda	001-38667	98-1463899
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Suite 1, 3^rd Floor 11-12 St. James’s Square London SW1Y 4LB United Kingdom		Not Applicable
(Address of Principal Executive Offices)		(Zip Code)

+44 (0) 207 400 3347

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, $0.000037453 par value	UROV	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 72.0102. ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

On February 11 12, 2021, Urovant Sciences Ltd., (or the “Company”), issued a press release announcing ~~that~~its ~~the~~financial ~~Data~~results ~~Safety~~for ~~Monitoring Board (“DSMB”) has recommended~~ the ~~continuation~~third offiscal ~~the~~quarter ~~Phase~~ended 2aDecember ~~study of URO-902~~31, ~~the Company’s novel gene therapy product candidate, in patients with overactive bladder and urge urinary incontinence~~2020. ~~Following~~The ~~the recommendation of the DSMB, the Company is proceeding with opening cohort 2 of the Phase 2a study with a dose of 48 mg or placebo. A copy of the~~ press release is ~~furnished~~attached as Exhibit 99.1 ~~to this Current Report on Form 8-K~~ and is incorporated herein by reference.

The information ~~being~~contained ~~furnished~~ in this Item 72.0102 ofand ~~Form~~in ~~8-K,~~the ~~including~~accompanying Exhibit 99.1, is furnished and shall not be deemed ~~to be “~~"filed”" for ~~the~~ purposes of Section 18 of the Securities Exchange Act of 1934, as amended ~~(the “Exchange Act”)~~, or ~~otherwise~~ subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, ~~nor~~as amended. The information in this Current Report shall itnot be incorporated by reference ~~into~~in aany filing ~~under~~with the U.S. Securities ~~Act~~and ofExchange ~~1933~~Commission ormade by the ~~Exchange Act~~Company, ~~except~~whether asmade ~~expressly~~before ~~set~~or ~~forth~~after bythe ~~specific~~date ~~reference~~hereof, regardless of any general incorporation language in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit		Description
99.1		Press Release, dated February 1112, 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		UROVANT SCIENCES LTD.
	Urovant Sciences Ltd.
Dated: February 11, 2021
Dated: February 12, 2021
	By:	~~By:~~/s/ Christine G. Ocampo	~~/s/ Christine G. Ocampo~~
		Christine G. Ocampo	~~Christine G. Ocampo~~
		Principal Accounting Officer	~~Principal Accounting Officer~~

Filing Compare · Urovant Sciences Ltd.